CN114587990A - 氧气杀菌装置 - Google Patents
氧气杀菌装置 Download PDFInfo
- Publication number
- CN114587990A CN114587990A CN202111547763.4A CN202111547763A CN114587990A CN 114587990 A CN114587990 A CN 114587990A CN 202111547763 A CN202111547763 A CN 202111547763A CN 114587990 A CN114587990 A CN 114587990A
- Authority
- CN
- China
- Prior art keywords
- human body
- anaerobic bacteria
- mask
- therapeutic gas
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 239000001301 oxygen Substances 0.000 title claims abstract description 38
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 38
- 230000001954 sterilising effect Effects 0.000 title abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 title description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims abstract description 59
- 208000015181 infectious disease Diseases 0.000 claims abstract description 22
- 230000029058 respiratory gaseous exchange Effects 0.000 claims abstract description 17
- 239000002344 surface layer Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000007789 gas Substances 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 241000238876 Acari Species 0.000 claims description 6
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 230000004089 microcirculation Effects 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 description 17
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001148470 aerobic bacillus Species 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000003103 anti-anaerobic effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229960002227 clindamycin Drugs 0.000 description 5
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 5
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 208000022506 anaerobic bacteria infectious disease Diseases 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229960004682 cefoperazone Drugs 0.000 description 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 3
- 229960005287 lincomycin Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000008836 maxillary sinusitis Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940007392 tylan Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940105296 zinc peroxide Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
- A61M16/0683—Holding devices therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
- A61H2033/143—Devices for gas baths with ozone, hydrogen, or the like with oxygen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
氧气杀菌装置,通过将人体表层的氧气浓度提高来杀死人体表层的厌氧菌,用面罩来保证正常呼吸。为了专门杀死脚部厌氧菌,将脚部包裹起来通入氧气来杀死厌氧菌。将封闭的手术室中的空气替换为氧气,用来防止手术过程中的感染,用面罩来保证正常呼吸。
Description
技术领域
本发明属于氧气杀菌领域,具体是利用是高浓度氧气杀死皮肤表层厌氧菌,同时避免吸入高浓度的氧气。
背景技术
厌氧菌(anaerobicbacteria)是一类在无氧条件下比在有氧环境中生长好的细菌,而不能在空气(18%氧气)和(或)10%二氧化碳浓度下的固体培养基表面生长的细菌。这类细菌缺乏完整的代谢酶体系,其能量代谢以无氧发酵的方式进行。它能引起人体不同部位的感染,包括阑尾炎、胆囊炎、中耳炎、口腔感染、心内膜炎、子宫内膜炎、脑脓肿、心肌坏死、骨髓炎、腹膜炎、脓胸、输卵管炎、脓毒性关节炎、肝脓肿、鼻窦炎、肠道手术或创伤后伤口感染、盆腔炎以及菌血症等。
厌氧菌尚无公认的确切定义,但通常认为这是一类只能在低氧分压的条件下生长,而不能在空气(18%氧气)和(或)10%二氧化碳浓度下的固体培养基表面生长的细菌。按其对氧的耐受程度的不同,可分为专性厌氧菌、微需氧厌氧菌和兼性厌氧菌。
1 厌氧菌的分类
1.1 对氧极端敏感的厌氧菌
1.2 中度厌氧菌
1.3 耐氧厌氧菌
2 厌氧菌感染 2.1 1.普遍存在
2.2 2.多为混合感染,需联合用药
2.3 3.牙周炎致病菌75%为厌氧菌
2.4 4.回肠、结肠细菌含量高
2.5 5. 易感染盆腔
3 厌氧菌治疗 3.1 (一)切除
3.2 (二)抗生素疗法
3.3 (三)高压氧疗法
厌氧菌的分类
根据对O2的耐受程度,可将厌氧菌分为3大类
对氧极端敏感的厌氧菌
代表菌种为月形单胞菌。这类细菌对厌氧条件要求很高,在空气中暴露10min即死亡,临床上很难分离出
中度厌氧菌
代表菌种为脆弱拟杆菌、产气荚膜梭菌等临床分离常见的厌氧菌。它们在空气中暴露60~90min或在脓汁抽出72h后仍然能分离出来
破伤风芽胞杆菌
耐氧厌氧菌
代表菌种为溶组织梭菌。这类细菌不能利用氧,在无氧条件下生长好,而在有氧条件下生长不佳。
厌氧菌感染
1.普遍存在
厌氧菌是人体正常菌群的组成部分,广泛存在于人体皮肤和腔道的深部黏膜表面,在组织缺血、坏死,或者需氧菌感染的情况下,导致局部组织的氧浓度降低,才发生厌氧菌感染。
抗厌氧菌类药物主要为硝基咪唑类,包括甲硝唑和替硝唑等。因为便宜,副作用小,不易产生细菌耐药,所以应用广泛,其中甲硝唑使用最多。厌氧菌感染,要用甲硝唑在治疗某些感染性疾病时,有时候即使使用再高级的抗生素,效果也不好,反而导致菌群失调,加重病情。这种情况,可能是因为我们忽视了对厌氧菌的治疗。
2.多为混合感染,需联合用药
由于甲硝唑被还原的中间产物对氧十分敏感,所以在有氧环境下容易失活,故只对厌氧菌发挥作用。但厌氧菌感染多为混合感染,即厌氧菌和需氧菌掺杂,两种细菌互相促进生长,因此在治疗厌氧菌感染时,须采用分别对需氧菌和厌氧菌敏感的药物,一般与头孢类药物合用,提高疗效。
由于厌氧菌培养需要一定的条件和时间,所以常在获得实验结果以前,医生已作出抗厌氧菌治疗的决定。因为感染的常见部位为口腔、腹腔、肠道及盆腔等,所以当这些部位发生感染性疾病时,治疗上一般会使用抗厌氧菌类药物。此外,当脓液或渗出液有腐败性臭味或甜味时,提示厌氧菌感染的可能性大。
3.牙周炎致病菌75%为厌氧菌
“口腔部位腔隙较多,利于细菌生长。”首都医科大学附属北京朝阳医院口腔科主任陈世璋说,研究显示,成年人牙周炎时,革兰氏阴性厌氧菌所占的比例,约为75%。
在口腔科炎症的治疗中,抗厌氧菌类药物应用比较普遍。主要用在以下方面:慢性成人牙周炎,口服甲硝唑或替硝唑,一周后停药,药效可以维持1―2周;慢性牙周炎急性发作,或由厌氧菌造成的严重感染性疾病,如颌面部的间隙厌氧菌感染、上颌窦炎等,需要与其他抗生素联合用药,静脉点滴3―5天。
4.回肠、结肠细菌含量高
胃肠道组织,几乎处在半封闭状态,氧气供应不好,所以厌氧菌容易生长。首都医科大学附属北京友谊医院普外科张忠涛主任说,肠蠕动使绝大多数细菌被送入下段肠道,因此,末端回肠及结肠细菌含量高,且99.9%为厌氧菌。
做直肠、结肠手术时,容易发生肠管破裂,或者需要手术切断,所以其内的厌氧菌可以进入腹腔。为了防止感染,此类手术前一般口服一天甲硝唑类药物预防感染,手术后还要继续静点天。
对于已被污染的手术操作,例如各种肠管破裂的急诊手术,肠管内的厌氧菌感染腹腔的可能性极大,因此在手术中,可以将甲硝唑液体倒入腹腔,进行浸泡和冲洗。
5. 易感染盆腔
“甲硝唑最早用于妇科阴道毛滴虫的治疗,所以又叫灭滴灵,后来发现,这个药还具有很好的抗厌氧菌作用。”首都医科大学附属北京妇产医院陈素文副主任医师说,因为盆腔组织临近直肠、肛门,容易感染到厌氧菌;盆腔解剖位置比较深,环境相对封闭、无氧,厌氧菌容易繁殖,在这种特殊的环境下,几乎大多数女性生殖道感染均不除外厌氧菌感染,所以抗厌氧菌类药物在妇科抗感染治疗中应用非常广泛,包括盆腔感染和阴道炎。
阴道炎治疗时,一般采用口服配合局部用药,7天为一个疗程;盆腔炎多与其他类抗生素联合静点,7―10天为一个疗程。
甲硝唑可能会导致胎儿畸形,怀孕前三个月和哺乳期最好不用,但阴道用栓剂相对安全。
段主任最后说,抗厌氧菌类药物的副作用,主要是消化道反应,如恶心、呕吐等;还可能会有锥体外系反应,如头痛、头晕等;无明显肝、肾功能损害,相对比较安全。
其他一些抗生素,如青霉素、氯霉素、克林霉素、头孢类、泰能等,也有抗厌氧菌的作用。但是这些药物抗菌谱比较广,容易导致菌群失调、霉菌感染等,所以不专门用作抗厌氧菌感染的治疗。
厌氧菌治疗
(一)切除
扩创和引流厌氧菌感染常伴有广泛的组织坏死,必须彻底切除,因坏死组织能降低局部Eh,有利于厌氧菌的繁殖,这是治疗厌氧菌感染的先决条件。产气荚膜杆菌性肌炎(即气性坏疽)时肌肉广泛坏死,也必须切除,严重的甚至需要截肢。坏死性筋膜炎是较少见的厌氧菌感染,筋膜和皮肤常有广泛坏死,如不彻底切除,常难以控制感染的扩散而导致死亡。
(二)抗生素疗法
抗生素必须选择对厌氧菌敏感的抗生素。厌氧菌对氨基糖甙类抗生素常有抗药性。[color=red]大多数厌氧菌,除脆弱类杆菌外,均对青霉素G敏感。林可霉素的抗菌谱与青霉素G相仿,如病人对青霉素过敏时可选用。氯霉素几乎对所有的厌氧菌包括脆弱类杆菌在内均有效,但缺点是有骨髓抑制的危险性。厌氧菌对四环素、红霉素和氯霉素的敏感性有差异,且在治疗过程中迅速产生抗药性,氯林可霉素对厌氧菌感染的疗效优于林可霉素,但它和林可霉素一样,有时会引起致命的假膜性结肠炎。在目前的抗菌药中,疗效最好的首推甲硝唑,对所有的厌氧菌包括脆弱类杆菌有效。Sharp等(1977)发现甲硝唑的疗效优于氯林可霉素和林可霉素,此药价格便宜,即使长期使用也无严重并发症。甲硝唑不仅可口服(500mg,每日三次),灌肠(每次~2g),最近国内已有静脉制剂,0.5%100ml,静滴每日~3次。口服甲硝唑和静脉滴注甲硝唑在结肠手术前准备中的作用,证明这两种方法均能有效地降低伤口的感染率。
前已述及,厌氧菌与需氧菌之间伴有协同作用,因此在治疗厌氧菌感染时须分别采用对需氧菌和厌氧菌敏感的药物。头孢西丁(Cefoxitin)对类杆菌属有效,但疗效不如氯林可霉素、氯霉素或甲硝唑。头孢孟多是一种新的静脉用头孢菌素,抗菌谱较广,对革兰氏阳性和革兰氏阴性的需氧菌和厌氧菌均有效。
第三代头孢菌素例如头孢羟羧氧酰胺(Moxalactam)头孢哌酮(Cefoperazone)和头孢噻肟(Cefotaxime)对需氧菌和厌氧菌均有效,对所有的厌氧菌均有极强的杀菌力(5)。
(三)高压氧疗法
高压氧能提高组织的氧张力,抑制厌氧菌的繁殖,这一疗法是梭形芽孢杆菌感染治疗中的一个重要方面,但对于无芽孢厌氧菌感染究竟有多少价值,不少人表示怀疑。(四)过氧化氢过氧化氢是治疗厌氧菌感染伤口的一种有效药物,它所释放的新生氧能杀死厌氧菌。过氧化锌糊剂则可用于治疗某些厌氧菌感染,特别是Meleney溃疡。
发明内容
本发明的目的是利用高浓度氧气杀死人体表层的病毒,细菌,螨虫,特别是厌氧菌。同时克服了人在富氧浓度以上无法正常呼吸的缺点。通过将人体表层的氧气浓度提高来杀死人体表层的厌氧菌,用面罩来保证正常呼吸。为了专门杀死脚部厌氧菌,将脚部包裹起来通入氧气来杀死厌氧菌。将封闭的手术室中的空气替换为氧气,用来防止手术过程中的感染,用面罩来保证正常呼吸。
病毒,细菌,螨虫,特别是厌氧菌高浓度氧气条件下会被氧化而失去活性。
高浓度的氧气可以杀死人体表层厌氧菌;高浓度的氧气可以改善人体表面的微循环;高浓度的氧气可以杀死跳蚤; 高浓度的氧气可以杀死人体表层螨虫。
附图说明
图1是杀死人体表层厌氧菌的结构示意图;
图2是脚部用纯氧杀死厌氧菌带阀门的结构示意图;
图3是脚部用纯氧杀死厌氧菌的结构示意图。
具体实施方式
第一种实施方式
人处在封闭环境内,边界(9)内充满治疗气体(8):呼吸面罩将鼻子,嘴巴,眼睛包围进去,所述呼吸面罩通过第一固定物(1),第二固定物(2),第三固定物(3),第四固定物(4)将面罩固定在脸上,通过进气管(5)导入新鲜空气,通过排气管(6)排出呼吸后的空气;所述治疗气体(8)为纯氧。
第二种实施方式
人处在封闭环境内,封闭环境内充满治疗气体:呼吸面罩将鼻子,嘴巴包围进去,呼吸面罩通过固定物将面罩固定在脸上,通过进气管导入新鲜空气,通过排气管排出呼吸后的空气,所述治疗气体为纯氧;简单的说就是第一种实施方式,面罩不包括眼睛。
第三种实施方式
防感染的手术室,手术室的封闭空间内充满防感染的治疗气体,手术室的封闭边界内放置手术设备,医护人员和患者使用面罩呼吸。
第四种实施方式
杀死脚部表层厌氧菌的脚套(15)有上部为绑扎口(13),所述脚套(15)连接阀门(11),阀门(11)连接接口(12),封闭空间(16)充满治疗气体(16)。
使用脚套(15)杀死厌氧菌的主要操作步骤;
1.把脚伸进脚套(15)内。
2. 把绑扎口(13)绑好,防止脚套(15)内治疗气体(16)通过绑扎口(13)排出。
3.打开阀门(11)。
4. 连接接口(12)与抽气机的连接,将脚套(15)内部空气抽出后关闭阀门(11)。
5. 断开连接接口(12)与接抽气机的连接。
6. 连接接口(12)与氧气瓶的连接。
7. 打开阀门(11)冲入适量的氧气。
8. 关闭阀门(11)。
9.等待治疗气体杀死脚部厌氧菌后。
10.解开绑扎口(13),把脚从脚套(15)拿出完成治疗。
第五种实施方式
杀死脚部表层厌氧菌的脚套(25)有上部为绑扎口(23),连接接口(27)在脚套(25),封闭空间(26)充满治疗气体。
使用脚套(25)杀死厌氧菌的主要操作步骤;
1.把脚伸进脚套(25)内。
2. 把绑扎口(23)绑好,防止脚套(25)内治疗气体(26)通过绑扎口(23)排出。
3.通过接口(27)抽出空气后通入纯氧
4. 等待治疗气体杀死脚部厌氧菌后。
5. 解开绑扎口(23),把脚从脚套(25)拿出完成治疗。
Claims (10)
1.一种改善人体表层微循环或杀死人体表层厌氧菌或杀死人体表层跳蚤或杀死人体表层螨虫的装置,其特征在于;人处于封闭空间内,封闭空间充满治疗气体,用面罩保证正常呼。
2.根据权利要求1所述,其特征在于;人处在封闭环境内,边界(9)内充满治疗气体(8):呼吸面罩将鼻子,嘴巴,眼睛包围进去,所述呼吸面罩通过第一固定物(1),第二固定物(2),第三固定物(3),第四固定物(4)将面罩固定在脸上,通过进气管(5)导入新鲜空气,通过排气管(6)排出呼吸后的空气;所述治疗气体(8)为氧气含量大于99%(%体积)。
3.一种防感染的手术室,其特征在于;手术室的封闭空间充满防感染的治疗气体,封闭边界内放置手术设备,医护人员和患者使用面罩呼吸。
4.一种封闭空间呼吸用面罩,其特征在于;面罩言有一根进气管,从封闭空间外引来,面罩含有一根排气管,将呼吸后的气体出。
5.根据权利要求4所述,其特征在于;面罩的罩体与脸部贴合并包围住鼻子和嘴巴。
6.根据权利要求4所述,其特征在于;面罩的罩体与脸部贴合并包围住鼻子和嘴巴和眼睛。
7.一种杀死脚部表层厌氧菌的脚套,其特征在于;脚套(25)有上部为绑扎口 (23),连接接口(27)在脚套(25),封闭空间(26)充满治疗气体。
8.一种杀死脚部表层厌氧菌的脚套,其特征在于;脚套(15)有上部为绑扎口 (13),所述脚套(15)连接阀门(11),阀门(11)连接接口(12),封闭空间(16)充满治疗气体。
9.一种杀死人体表层厌氧菌或杀死人体表层跳蚤或杀死人体表层螨虫的治疗气体,其特征在于;氧气含量大于99%。
10.一种杀死人体表层厌氧菌的治疗气体,其特征在于;氧气含量大于23.5%(%体积)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111547763.4A CN114587990A (zh) | 2021-12-17 | 2021-12-17 | 氧气杀菌装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111547763.4A CN114587990A (zh) | 2021-12-17 | 2021-12-17 | 氧气杀菌装置 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114587990A true CN114587990A (zh) | 2022-06-07 |
Family
ID=81814297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111547763.4A Pending CN114587990A (zh) | 2021-12-17 | 2021-12-17 | 氧气杀菌装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114587990A (zh) |
-
2021
- 2021-12-17 CN CN202111547763.4A patent/CN114587990A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scopp et al. | Gingival degerming by povidone-iodine irrigation: bacteremia reduction in extraction procedures | |
MX2007007606A (es) | Dispositivo y metodo para el tratamiento de heridas con oxido nitrico. | |
KR20070003815A (ko) | 치료제 투여 장치 및 방법 | |
EP3164139B1 (en) | Topical compositions and methods for treating wounds | |
EP2509622A2 (en) | Inhibiting bacterial infection and biofilm formation | |
Cline et al. | Clostridial myonecrosis | |
CN109985069B (zh) | 益生菌组合物及其用途 | |
Umeda et al. | Toxic shock syndrome after suction lipectomy | |
CN105263489B (zh) | 抗微生物组合物及其制造方法 | |
Mohanty et al. | Comparison of 2 g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gardnerella vaginalis | |
NZ552764A (en) | Composition comprising lactic acid and lactoferrin | |
CN114588253A (zh) | 用于修复和预防阴道粘膜衰老的药物组合物及其制剂 | |
CN114587990A (zh) | 氧气杀菌装置 | |
Tapia | Ozone therapy in the treatment of recurrent vulvo-vaginitis by Candida albicans | |
Arrosagaray et al. | Bilateral abscessed orchiepididymitis associated with sepsis caused by Veillonella parvula and Clostridium perfringens: case report and review of the literature | |
Garrod | Chemoprophylaxis | |
Velitchkov et al. | Toxic shock syndrome and necrotizing fasciitis complicating neglected sacrococcygeal pilonidal sinus disease: report of a case | |
MAKSUDOV et al. | Development of a comprehensive programme for the comprehensive treatment of patients with maxillofacial phlegmon with viral hepatitis B | |
Khairy et al. | Vaginal ozone insufflation in the treatment of recurrent candidal vulvovaginitis: Randomized control trial | |
EP4167932A1 (en) | Antimicrobial combinations | |
CN111632073A (zh) | 一种抗菌消炎的女性私密益生菌组合物及其制备 | |
KR102014810B1 (ko) | 질염 예방 및 치료용 조성물 | |
RU2391977C2 (ru) | Способ лечения острых форм бактериальных вагинитов | |
Muhvich et al. | Effect of hyperbaric oxygenation, combined with antimicrobial agents and surgery, in a rat model of intraabdominal infection | |
임현경 et al. | Cefepime-induced neurotoxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220607 |
|
WD01 | Invention patent application deemed withdrawn after publication |